Log in
Enquire now
‌

US Patent 11667687 Masked activatable interferon constructs

Patent 11667687 was granted and assigned to CytomX Therapeutics on June, 2023 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
CytomX Therapeutics
CytomX Therapeutics
0
Current Assignee
CytomX Therapeutics
CytomX Therapeutics
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
116676870
Date of Patent
June 6, 2023
0
Patent Application Number
176962220
Date Filed
March 16, 2022
0
Patent Citations
‌
US Patent 8734774 Protease activated cytokines
0
‌
US Patent 8809504 Inhibitor which is deactivatable by a reagent produced by a target cell
0
‌
US Patent 9453078 Modified antibody compositions, methods of making and using thereof
0
‌
US Patent 9675672 Compositions and methods for modulating gamma-C-cytokine activity
0
‌
US Patent 10059762 Anti-EGFR activatable antibodies
0
‌
US Patent 10077300 Activatable binding polypeptides and methods of identification and use thereof
0
‌
US Patent 10118961 Modified antibody containing the cleavable peptide with the amino acid sequence TGRGPSWV
0
‌
US Patent 10513549 Cleavage-activatable interferon-alpha proprotein
0
...
Patent Citations Received
‌
US Patent 12091442 Activatable cytokine constructs and related compositions and methods
0
Patent Primary Examiner
‌
Elly-Gerald Stoica
0
CPC Code
‌
C07K 14/555
0
‌
C07K 2319/50
0
‌
C07K 2319/00
0

Provided herein are activatable cytokine constructs that include: (a) a first monomer construct comprising a first peptide mask (PM1), a third cleavable moiety (CM3), a first mature cytokine protein (CP1), a first cleavable moiety (CM1), and a first dimerization domain (DD1), wherein the CM1 is positioned between the CP1 and the DD1, and the CM3 is positioned between the PM1 and CP1; and (b) a second monomer construct comprising a second mature cytokine protein (CP2), a second cleavable moiety (CM2), and a second dimerization domain (DD2), where the CM2 is positioned between the CP2 and the DD2, where: the DD1 and the DD2 bind each other; and where the ACC is characterized by a reduction in at least one activity of the CP1 and/or CP2 as compared to a control level of the at least one activity of the CP1 and/or CP2.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11667687 Masked activatable interferon constructs

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.